Table 1.
Ongoing trials of chemotherapy with or without targeted therapy in advanced BTC
| Regimen | Phase | Trial ID | Design |
|---|---|---|---|
| Trifluridine/Tipiracil/Irinotecan | II | NCT04059562 | AC |
| Trifluridine/Tipiracil | II | NCT04076761 | AC |
| FOLFIRINOX | II | NCT04305288 | AC |
| FORFIRINOX | II | NCT03772132 | BD |
| Nal-IRI/5-FU/leucovorin | II | NCT03043547 | AC |
| Irinotecan/Trifluridine and Tipiracil | II | NCT04072445 | AC |
| Nal-Irinotecan/Trifluridine and Tipiracil | I/II | NCT03368963 | AC |
| Chemotherapy/EphB4-HAS/ | I | NCT02495896 | AC |
| GemCis + Copanlisib | II | NCT02631590 | AC |
| GemCis/Anetumab ravtansine | I | NCT03102320 | BD |
| FORFIRINOX/target agents | II | NCT03768375 | BD |
| GEMOX/target agents | II | NCT02836847 | BD |
| GemCis/Ivosidenib/Pemigatinib | I | NCT04088188 | BD |
| GemCis/CPI 613 | I/II | NCT04203160 | AC |
| GemCis/CX-4945 | I/II | NCT02128282 | AC |
| GemCis/Pemigatinib | I/II | NCT02393248 | BD |
| Carboplatin/Paclitaxel/Pevonedistat | II | NCT04175912 | AC |
| GemCis/FT-2102 | I/II | NCT03684811 | BD |
FORFIRINOX folinic acid, fluorouracil, irinotecan, oxaliplatin, nal-IRI liposomal irinotecan, GemCis gemcitabine cisplatin, GEMOX gemcitabine oxaliplatin, AC all-comers, BD biomarker driven